The classification of glomerulonephritis in systemic lupus erythematosus revisited, J Am Soc Nephrol, vol.15, pp.241-50, 2004. ,
Non HCVrelated infectious cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey and systematic review of the literature, J Autoimmun, vol.65, pp.74-81, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02032951
C3 glomerulopathy: a new classification, Nat Rev Nephrol, vol.6, pp.494-503, 2010. ,
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome, J Med Genet, vol.44, pp.193-202, 2007. ,
Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients, Clin J Am Soc Nephrol, vol.4, pp.22-32, 2009. ,
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, vol.82, pp.454-64, 2012. ,
Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H, Nat Genet, vol.31, pp.424-432, 2002. ,
The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion, Am J Pathol, vol.161, pp.2027-2061, 2002. ,
Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice, Kidney Int, vol.78, pp.279-86, 2010. ,
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice, J Clin Invest, vol.118, pp.608-626, 2008. ,
Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases, J Immunol, vol.194, pp.5129-5167, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01843975
Combined C3b and factor B autoantibodies and MPGN type II, N Engl J Med, vol.365, pp.2340-2342, 2011. ,
Toward a working definition of C3 glomerulopathy by immunofluorescence, Kidney Int, vol.85, pp.450-456, 2014. ,
, C3 glomerulopathy: consensus report, vol.84, pp.1079-89, 2013.
Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk, Kidney Int, vol.69, pp.504-515, 2006. ,
C3 glomerulonephritis associated with monoclonal gammopathy: a case series, Am J Kidney Dis, vol.62, pp.506-520, 2013. ,
Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis, J Exp Med, vol.175, pp.939-50, 1992. ,
Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H, J Immunol, vol.163, pp.4590-4596, 1999. ,
Effectiveness of mycophenolate mofetil in C3 glomerulonephritis, Kidney Int, vol.88, pp.1153-60, 2015. ,
Recurrent membranoproliferative glomerulonephritis after kidney transplantation, Kidney Int, vol.77, pp.721-729, 2010. ,
New approaches to the treatment of dense deposit disease, J Am Soc Nephrol, vol.18, pp.2447-56, 2007. ,
Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression, Pediatr Nephrol, vol.30, pp.1951-1960, 2015. ,
Rituximab fails where eculizumab restores renal function in C3nef-related DDD, Pediatr Nephrol, vol.29, pp.1107-1118, 2014. ,
Eculizumab in a patient with dense-deposit disease, N Engl J Med, vol.366, pp.1161-1164, 2012. ,
Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice, Proc Natl Acad Sci, vol.103, pp.9649-54, 2006. ,
Eculizumab for treatment of rapidly progressive C3 glomerulopathy, Am J Kidney Dis, vol.65, pp.484-493, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01843971